Rezera Inc.
Rezera Inc. operates as a clinical stage biotechnology company. Its pipeline includes ruvonoflast, an oral inhibitor of NOD-like receptor protein 3, which is the upstream driver of sterile inflammation that is caused by damage signals, such as cholesterol crystals or misfolded proteins in the patients suffering with peripheral artery disease; and trabzanoflast, an NLRP3 inhibitor designed to be brain-penetrant and achieve central nervous system exposure and selective upstream inhibition of NLRP3-driven neuroinflammation. Rezera Inc. was formerly known as NodThera Inc. and changes its name to Rezera Inc. in September 2026. The company was founded in 2016 and is based in Boston, Massachusetts.
No SEC Form 4 filings for $RZRA in the last 30 days.
See all $RZRA insider activity →Rezera Inc. set an IPO price range of $11 to $13 per share, aiming to raise $200 million on Nasdaq. The offering is led by four underwriters. The final price may vary based on demand during the roadshow.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RZRA (Rezera Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Rezera Inc. set an IPO price range of $11 to $13 per share, aiming to raise $200 million on Nasdaq. The offering is led by four underwriters. The final price may vary based on demand during the roadshow.
AlphAI scores every news story that mentions RZRA with an AI model for sentiment and relevance, and aggregates insider trades from Rezera Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rezera Inc. set an IPO price range of $11 to $13 per share, aiming to raise $200 million on Nasdaq. The offering is led by four underwriters. The final price may vary based on demand during the roadshow.
